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Abstract
Background: Migrants form a substantial proportion of the population affected by the human immunodeficiency virus (HIV)
epidemic in Europe, yet HIV prevention for this population is hindered by poor understanding of access to care and of postmigration
transmission dynamics.
Objective: We present the design and methods of the advancing Migrant Access to health Services in Europe (aMASE) study,
the first European cross-cultural study focused on multiple migrant populations. It aims to identify the structural, cultural, and
financial barriers to HIV prevention, diagnosis, and treatment and to determine the likely country of HIV acquisition in HIV-positive
migrant populations.
Methods: We delivered 2 cross-sectional electronic surveys across 10 countries (Belgium, France, Germany, Greece, Italy, the
Netherlands, Portugal, Spain, Switzerland, and United Kingdom). A clinic survey aimed to recruit up to 2000 HIV-positive
patients from 57 HIV clinics in 9 countries. A unique study number linked anonymized questionnaire data to clinical records data
(viral loads, CD4 cell counts, viral clades, etc). This questionnaire was developed by expert panel consensus and cognitively
tested, and a pilot study was carried out in 2 countries. A Web-based community survey (n=1000) reached those living with HIV
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but not currently accessing HIV clinics, as well as HIV-negative migrants. It was developed in close collaboration with a community
advisory group (CAG) made up of representatives from community organizations in 9 of the participating countries. The CAG
played a key role in data collection by promoting the survey to higher-risk migrant groups (sub-Saharan Africans, Latin Americans,
men who have sex with men, and people who inject drugs). The questionnaires have considerable content overlap, allowing for
comparison. Questions cover ethnicity, migration, immigration status, HIV testing and treatment, health-seeking behavior, sexual
risk, and drug use. The electronic questionnaires, which were available in 15 languages, allowed for complex routing, preventing
respondents from answering irrelevant questions.
Results: In total, we recruited 2249 participants from 57 HIV clinics as part of the clinic survey and retrieved 1637 complete
responses as part of the community survey.
Conclusions: The findings will provide much-needed information for improving HIV prevention interventions and access to
services for migrant communities.
(JMIR Res Protoc 2016;5(2):e74)   doi:10.2196/resprot.5085
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Introduction
In 2014, with new human immunodeficiency virus (HIV)
infections on the decline, the Joint United Nations Programme
on HIV/AIDS (UNAIDS) announced the beginning of the end
of the AIDS epidemic [1]. Although there are still approximately
35 million people living with HIV worldwide, UNAIDS has set
a goal of ending the AIDS epidemic in “every region, every
country, in every location, in every population and every
community” by 2030 [1]. Reaching this ambitious goal is now
possible because of vast improvements in the ability to provide
widespread HIV testing and subsequent treatment with
antiretroviral therapy. Within Europe, the end of AIDS is
dependent on identifying, treating, and preventing onward
transmission among an estimated 2.2 million people living with
HIV [2], a substantial and disproportionate number of whom
are people who were born in another country, that is, migrants.
While 9.7% of the European Union (EU)/European Economic
Area population were born outside the current borders of their
country of residence [3], over a third (35.0 %) of those newly
diagnosed with HIV in 2013 were migrants [4]. Approximately
15% of those were people who had migrated from a country
with a generalized epidemic, notably sub-Saharan Africa (13%).
Smaller proportions of newly diagnosed migrants were from
Central and Eastern Europe (5.1%), Latin America and the
Caribbean (4.9%), other Western European countries (3.9%),
and South and Southeast Asia (2.2%) [4].
Despite the heavy burden of HIV among migrant communities,
HIV prevention and treatment for these populations is hindered
by a relatively sparse evidence base and the heterogeneity of
the populations affected [5]. Migrants are more likely to be
exposed to social determinants of ill health (such as poverty,
social exclusion, and unemployment), which can result in poor
health-seeking behaviors [6]. Other structural factors such as
legal and administrative status, together with health care- and
community-related barriers, can further prevent migrants from
accessing health services, particularly HIV testing [7]. Yet little
is known about migrant access to health services, particularly
HIV testing, access to treatment, and safer sex practices [8].
Previously it had been assumed that most HIV diagnosed among
migrants in Europe was acquired in the country of origin,
particularly those born in sub-Saharan Africa. Yet it is unclear
whether infections are acquired pre- or postmigration [5].
Although surveillance data show that people living outside their
country of birth form a substantial proportion of the population
affected by the HIV epidemic in Europe, limited data are
available about migrant populations to inform policy and
practice for these communities.
Understanding barriers to accessing HIV care and postmigration
transmission dynamics will provide policy makers and program
managers much-needed evidence for effectively planning HIV
prevention programs for migrant communities. Several
cross-sectional sexual health and HIV studies have sampled
migrant populations, but these were often limited to migrants
from 1 region (black Africans in Burns et al [9] or Central and
Eastern Europeans in Evans et al [10]) or migrants in 1 country
(Dray-Spira et al [11]), and there has not been a collaborative
European study to address these research questions jointly.
Within the European Network of HIV/AIDS Cohort Studies to
Coordinate at European and International Level Clinical
Research on HIV/AIDS (EuroCoord), we set up the advancing
Migrant Access to health Services in Europe (aMASE) study
whose overall aim is to provide the evidence to prevent HIV
infection and improve diagnosis and prognosis of migrant
populations living with HIV in Europe in order to support policy
development at the European level. Specifically, aMASE aims
to identify the structural, cultural, and financial barriers to HIV
prevention, diagnosis, and treatment and to determine the likely
country of HIV acquisition in HIV-positive migrant populations.
In this paper, we present the design and methods of the 2
cross-sectional studies that form aMASE and the unique
challenges associated with multisite, multidisciplinary,
multinational research.
Methods
Study Design
aMASE is formed of 2 cross-sectional, electronic surveys of 2
populations: (1) migrant adults living with HIV and attending
HIV services (the clinic survey), and (2) migrant adults living
in Europe (the community survey). For the purposes of this
study, we define migrants as foreign-born individuals intending
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to live in their current country of residence for ≥6 months.
Residency was not dependent on formal documentation, and
immigration status, while captured within the survey, was not
part of the inclusion or exclusion criteria. The clinic survey was
delivered using a computer-assisted self-interview (CASI) or
computer-assisted personal interview (CAPI) and augmented
with clinical data from patient records. The community study
was a Web-based survey designed to reach those living with
HIV but not currently accessing HIV clinics, as well as
HIV-negative migrants.
Clinic Survey
Study Setting and Time Period
The clinic survey was implemented in 57 clinics in 9 countries
(Belgium, Germany, Greece, Italy, the Netherlands, Portugal,
Spain, Switzerland, and the United Kingdom) between July
2013 and June 2015. Multimedia Appendix 1 lists the clinics’
names.
Participants and Eligibility Criteria
Patients were eligible for inclusion in the study if they were (1)
HIV-positive, (2) aged ≥18 years, (3) foreign-born and resident
in the country of recruitment for ≥6 months, (4) diagnosed
within 5 years of the study date, and (5) able to complete, either
alone or supported, a CASI in any of the 15 languages available
(Amharic, Arabic, Dutch, English, French, German, Greek,
Italian, Polish, Portuguese, Russian, Turkish, Tigrinya, Spanish,
and Somali). In Switzerland, local eligibility criteria applied
(migrants from neighboring Austria, France, Germany, and Italy
are excluded due to close linguistic and cultural ties).
Sample Size
The sample size calculation was based on precision and used
the standard formula for standard error of a proportion: SE=Sqrt
(p*(1–p)/n). In calculating the sample size, the primary outcome
measures were health service use (registered with primary care
physician) and the proportion of participants with a previous
negative HIV test.
Initially we anticipated recruiting 4000 participants (2000 men
and 2000 women) from 2 to 5 clinics in each of 7-9 EU countries
(creating about 40 clusters). We considered the within-cluster
correlation likely to be relatively weak (eg, 0.005), at least for
regression analyses, as the average cluster size may potentially
have been large (eg, 75-125). Assuming a design effect of 1.5
for the study, the overall effective sample size would have been
~2670. This sample size would have provided good precision
for our estimates. Specifically, within each gender group, our
outcomes could be estimated to within 3% across Europe and
to within around 8% for each country. As recruitment was
slower than anticipated, to a large extent due to the decrease in
the number of new HIV-positive migrants in Europe [12], we
revised this sample size in December 2014.
The revised target sample size calculation was 2000 participants
(1000 men and 1000 women) from all clinics. We recruited
participants from a minimum of 2 clinics in each of the 9
countries, with each clinic forming a discrete cluster. We
estimated this within-cluster correlation also to be relatively
weak (eg, 0.005), at least for regression analyses including
patient and city characteristics as covariates. As the average
cluster size was likely to be smaller than first estimates (eg,
40–60), we assumed a design effect of 1.25 for the study and,
hence, an overall effective sample size of ~1600. This revised
sample still provides good precision for estimates. Specifically,
within each gender group, we will be able to estimate our
outcomes to within 3.5% across Europe and to within 10% for
each country.
Sampling Strategy
The main inclusion criteria for study sites were a sizable migrant
clinic population (sufficient to recruit a minimum of 40 study
participants in most sites) and the human resource capacity to
conduct the study with minimal additional funding. Eligible
patients attending participating clinics within the study period
were approached by members of their clinical care team or a
recruitment researcher to participate in the clinic survey.
Variables and Questionnaire Development
We formed a working group, made up of international experts
and EuroCoord collaborators, to act as an expert panel tasked
with reaching consensus on survey instrument development and
provide overall supervision of the study. Where possible, we
adapted questionnaire items from existing survey instruments.
New questions were drafted by the core research team and expert
panel members.
We validated the questionnaire using cognitive testing (cognitive
aspects of survey methodology approach [13]). It was tested in
Spanish (in Spain) and English (in the United Kingdom) on 7
black African and 3 Latin American migrants recruited from
community-based HIV service organizations. The finalized
patient questionnaire is divided into 3 sections: (1) detailed
sociodemographic data and extensive migration history data,
(2) sexual and HIV risk behavior, including drug use before and
after migration, and (3) service use and experiences of living
with HIV, including stigma and discrimination. Questions were
tailored to reflect the different health care or ethical approval
systems in different countries. For example, respondents
completing the survey in Portugal were not asked questions
about ethnicity or health care costs. There are 90-92 items
included depending on current country of residence, although
through skipping and filters some respondents answered as few
as 43 questions. Most questions were closed and the survey
completion time was between 15 and 50 minutes depending on
the language selected. The survey was translated from English
into 15 languages (see Participants and Eligibility Criteria above)
by a professional translation company. These translations were
then checked by a different translation company, who
back-translated a portion of the questionnaire into English to
ensure quality control.
Participating patients’ questionnaires were matched to a clinical
data form using a unique study number. The clinical data form
contains 20 items, including CD4 cell count and viral load (at
diagnosis, at antiretroviral therapy initiation, and the latest
available); previous HIV-negative tests and viral clade;
AIDS-defining illnesses and coinfections; and treatment
initiation. Clinical data were completed electronically.
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Ethics
Ethical approval for the aMASE studies was received separately
in each participating country (see Table 1).
Pilot Study
We piloted the function and reliability of the CASI and the
clinical data form in 3 clinics (2 in London, 1 in Madrid) with
115 patients. The pilot study also tested whether recruitment
procedures, study implementation, and data collection, storage,
and handling methods were feasible and appropriate. Following
feedback about the function of the CASI software from
recruitment researchers, we redesigned the survey using new
CASI software. To facilitate recruitment, the selection criterion
of HIV diagnosis in the previous 3 years was increased to 5
years. Based on the results of the pilot study, the survey
questions remained essentially the same; however, we
redesigned some items to produce a better user experience.
Study Implementation
The patient questionnaire was administered using tablets,
computers, or laptops running Fluidware version 5.0
(SurveyMonkey Canada Inc, Ottawa, ON). Enrollment
commenced in participating clinics in July 2013 and was
completed in July 2015.
As of August 2015, there were 57 participating clinics in 9
countries: Belgium (n=4), Germany (n=2), Greece (n=8), Italy
(n=2), the Netherlands (n=3), Portugal (n=7), Spain (n=18),
Switzerland (n=6), and the United Kingdom (n=7).
A study coordinator at the Institute of Health, Carlos III, Spain,
was responsible for the overall management of the fieldwork,
but in each country a nominated country lead (usually a member
of the expert panel) was responsible for collating data across
clinics in his or her country. This coordinator actively engaged
with all participating centers and country leads to ensure
compliance with the study standards, and identified aspects that
needed improvement throughout the study period. Where
necessary, clinics were supplied with laptops and tablets
preloaded with CASI software and instructions for use. Clinics
were given a clinic study pack (developed during the pilot
study), which detailed the general protocol and maintenance
instructions for the CASI devices. Clinic recruiters were able
to access an online Web resource with electronic versions of all
the required documentation for the study. Incentives were not
provided to participants, although some clinics supported
travelling costs in the context of their research practices.
Recruitment procedures varied slightly across countries and
between clinics, but in general recruitment and consent
procedures were as follows.
Eligible patients were identified though clinic databases and
their clinical records were flagged. Clinic numbers of eligible
patients were noted next to precoded unique study numbers on
an enrollment log. Eligible patients were then approached by
either members of their clinical care team or a recruitment
researcher and provided with a patient information sheet and
the opportunity to ask questions. Patients who declined to
participate had their age, ethnicity or nationality, and gender
noted on the enrollment log. Those who agreed to participate
were asked to complete the CASI/CAPI on site. In most
countries, ethical approval for obtaining informed consent
through a tick box in the questionnaire was given; however, in
Belgium, Switzerland, Greece, and Germany local ethical
approval standards required separate consent forms.
Enrollment logs were stored in a locked cabinet; electronic
versions of the completed forms were returned to the study
coordinator on a monthly basis. Survey data were either captured
and then stored directly on a central secure database operated
by FluidSurveys (online questionnaire) or stored on the device’s
hard drive until they were transferred to a secure network in
Madrid (offline questionnaire).
Statistical Analysis
We will explore barriers to accessing health care by using the
primary outcomes measures: access to a primary care physician
and a previous negative HIV test.
Participating clinics are not necessarily representative of the
number of clinics within countries or, indeed, the migrants living
with HIV within those countries. For these reasons, the overall
sample prevalence of our primary outcome measures, pooled
across countries and clinics, may not be informative. We shall
give it emphasis in our results only if the prevalence across
countries is similar and otherwise focus on the prevalence in
each country. We anticipate that associations with the primary
outcomes, for example their association with age, will be broadly
comparable across countries. However, if associations differ
substantially between countries, then we shall investigate this
heterogeneity and report an overall measure of association if
we judge this to be meaningful. Furthermore, as men and women
are expected to have different barriers to accessing care, we will
analyze them separately. We will analyze individuals who
identify as transsexual separately if numbers are sufficient. We
will conduct analyses separately by region of birth if associations
differ substantially by region, and we may conduct separate
analyses for men who do and do not have sex with men if
associations differ substantially between these 2 groups of
participants.
Our interest is in associations between the primary outcome
measures and each of the following factors: age, gender, region
of birth, sexual orientation, immigration status, and age at
migration or diagnosis. We will first describe these associations
through cross-tabulations. To acknowledge the clustering of
participants, we shall analyze associations using hierarchical
random effects logistic regression, with a random effect for
clinics nested within countries, analyzing factors individually
and then jointly in a multiple regression model. We will report
associations as odds ratios with 95% CIs.
Within EuroCoord, a group of experts has been established to
develop and evaluate a reliable algorithm to determine probable
country of infection. The algorithm will incorporate
demographic (eg, gender, race or ethnicity, age) and clinical
data (eg, CD4 counts, HIV RNA levels, clinical stage according
to the US Centers for Disease Control and Prevention) and will
be evaluated in simulation studies and in cohorts with
well-estimated seroconversion dates. The algorithm will be
further elaborated using data from the questionnaire (eg,
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migration and HIV testing history, sexual partners pre- and
postmigration). CD4 cell counts and viral loads for the study
participants will be extracted from the clinical records. Methods
for calculating a proxy date for seroconversion rely on clinical
parameters with very little, if any, behavioral information
informing the model [14]. Our analysis will draw on more
detailed information than what is available in routinely collected
surveillance data, thus allowing for a more nuanced approach
in determining probable country of infection. We will use
imputation methods to account for missing data in clinical
records. Further details on the methodology used to develop,
verify, and apply the algorithm will be published separately.
Response Rates
The age, nationality or ethnicity, and gender of all patients
approached to participate in the study were noted on a clinic
log. We will analyze these data to assess whether those who
agreed to participate are significantly different from those who
declined.
Community Survey
Study Setting and Time Period
We designed the aMASE community survey to complement
the clinic survey and capture data on all migrants regardless of
their HIV status. The community survey was available through
Web browsers between April 2014 and July 2015.
Participants and Eligibility Criteria
All migrants living in the World Health Organization European
area (52 countries) aged ≥18 years, irrespective of their HIV
status or current country of residence, were eligible to participate
in the aMASE community survey.
Sample Size
No sampling frame for migrants in Europe exists, so we used
a convenience sampling strategy. The main outcome measures
on which we based our sample size estimates were registration
with a primary care physician and ever having tested for HIV.
The community survey aimed to recruit 1000 migrants, which
allows for estimates of outcomes by gender to within 5%. This
sample size also provided 80% power to detect a difference of
6% in 1 of the key outcomes (assuming an overall outcome
prevalence of 50%) compared with service users (in the clinic
study), or smaller differences for less prevalent outcomes.
Sampling Strategy
We actively promoted the survey from June 2014 to May 2015
using social marketing and community participatory methods
in 9 countries: Belgium, France, Germany, Greece, Italy, the
Netherlands, Portugal, Spain, and the United Kingdom. We
targeted some of these countries for active promotion because
they were also involved in clinic recruitment. An ongoing survey
with African migrants in Switzerland precluded active promotion
in that country, and we selected France because it has a large
migrant population. A community advisory group (CAG), a
group of individuals working for local community-based
organizations that provide services to migrant communities or
oversee pan-European migrant or HIV networks, was integral
to the sampling strategy. The aMASE expert panel selected
CAG members with representation from all countries involved
in active promotion of the survey. CAG members were
contracted to deliver outreach meetings, with the aim of
promoting the survey to other organizations within their country.
In turn, these organizations promoted the survey to other
organizations and their service users and cascaded the study
promotion in a method similar to snowball sampling.
Variables and Questionnaire Development
We developed the community survey instrument using an
iterative community participatory approach involving the CAG
and the expert panel. The expert panel was responsible for the
survey content and design and all technical aspects of
administering the questionnaire. The CAG ensured that the
survey content was relevant to migrant communities within
Europe and provided a “real-world” critique of the survey items.
The CAG was able to highlight culturally insensitive questions
(eg, increasing the number of available gender categories from
2 to 6) or request items that will provide findings that can be
quickly translated into policy and practice recommendations
(eg, knowledge about access to free condoms). After 4 iterations
of the survey development process, we tested the survey CASI
for programming inconsistences. The survey was then translated
into 14 languages (identical to the clinic survey with the
exclusion of Tigrinya) by a professional translation company.
These translations were then checked by members of the CAG
or colleagues fluent in the available languages. Almost
three-quarters (66/93) of the items in the clinic survey patient
questionnaire are replicated in the community questionnaire to
allow for comparison between the 2 samples. The remaining
items include country-specific questions and topics of interest
to the CAG and cover health service use in the country of origin
or residence; home testing or sampling for HIV and other
infections; mental health; and social determinants of health (eg,
housing).
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Table 1. Ethical approval for the advancing Migrant Access to health Services in Europe (aMASE) study in each country.
NumberCommitteeCountry
911/13Institute of Tropical Medicine, Institutional Review BoardBelgium (Antwerp)
B076201215754Comité local d’éthique hospitalier, Centre Hospitalier Universitaire Saint-PierreBelgium (Brussels)
B076201215754Universitair Ziekenhuis Gent, Commissie voor Medische EthiekBelgium (Gent)
B707201318791Comité local d’éthique Hospitalo-Facultaire Universitaire de LiègeBelgium (Liège)
008/14Rheinische Friedrich-Wilhelms-Universität Bonn, Medizinische Fakultat Ethik-
Kommission
Germany (Bonn)
6/3/2013a(# 6313)National and Kapodistrian University of Athens Institutional Review BoardGreece
22/02/2013aIstituto Nazionale per le Malattie Infettive “Lazzoro Spallanzani”Italy
2013_137#C20131038Universiteit van AmsterdamThe Netherlands
28/8/2013aCentro Hospitalar de São João, EPEPortugal
31/8/2013aHospital Prof. Doutor Fernando Fonseca, EPEPortugal
9/10/2013aCentro Hospitalar Lisboa Norte, EPEPortugal
11/7/2013aCentro Hospitalar Lisboa Central, EPEPortugal
21/1/2015aCentro Hospitalar de Setúbal, EPEPortugal
14/10/2014a
Comissão Nacional de Proteção de Dados (Portuguese Data Protection Authority),
EPEPortugal
CEI PI 01_2012-v2Comité de Ética de la Investigación y del bienestar animal, Instituto de Salud Carlos
III
Spain
024/13Kantonale Ethikkommission BernSwitzerland
11/LO/1600London-Bentham Research Ethics CommitteeUnited Kingdom
aDate of approval letter.
Ethics
Ethical approval was obtained from the London Bentham
Research Ethics Committee (11/LO/1600). Additional approvals
were obtained in all countries also undertaking the clinic survey.
Pilot Study
We carried out a short pilot study with CAG and expert panel
members (38 respondents) who completed the survey in a
language of their choice. The CASI was revised to improve the
quality of translations and make them more suitable for our
target population.
Study Implementation
EuroCoord’s primary community partner, the European AIDS
Treatment Group (a European network of nationally based
volunteer activists), employed a project coordinator to assist
the research team in community engagement and chair the CAG.
CAG members were provided with a suite of promotional
materials including posters, business cards, postcards, and
electronic banner advertisements, which were available from
the aMASE website. Over 18,000 small media items (3100
business cards; 15,600 postcards) were printed and disseminated
to community-based organizations across Europe. The CAG
also used additional promotional and recruiting strategies: for
example, 12 organizations (in France, the Netherlands, Greece,
and the United Kingdom) allowed participants to complete the
survey on laptops or other devices on their premises.
We contacted a further 243 community-based organizations
identified through a mapping exercise and asked them to
promote the survey on their websites and social media pages
(eg, Facebook, Twitter). Approximately 300 webpages and apps
also carried banner advertisements or links for the community
survey, including PlanetRomeo, Grindr, Poz Traveler, and
EasyExpat.
All community survey promotional materials referenced the
aMASE website, where potential participants were able to select
1 of the 14 survey languages on the initial landing page [15].
Participant information sheets about the community survey were
available in all 14 survey languages. Further information with
in-depth details about both cross-sectional surveys was available
in Dutch, English, French, German, Italian, Portuguese, and
Spanish. Individuals who wished to participate in the study
clicked through to a separate website, where the survey is hosted
by FluidSurveys. All participants provided within-survey tick
box consent. Survey data were captured and then stored directly
on a central secure database operated by FluidSurveys.
Statistical Analysis
Statistical analysis will follow similar methods to those outlined
for the clinic survey. Direct comparisons between the clinic
population and the community population in the primary
outcome measures may identify additional barriers to accessing
health care, especially HIV testing, treatment, and care.
Secondary outcomes explored in the community survey include
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chronic illness and infection other than HIV; access to condoms;
access to needle exchange programs; and experiences of racism
and homophobia.
Funding
The aMASE study is part of Work Package 14 of EuroCoord,
which is funded by the EU’s Seventh Framework Programme
for research, technological development, and demonstration
(under grant no. 260694). The community mobilization and
engagement project was sponsored by Gilead Sciences Europe
Ltd. Multimedia Appendix 2 lists other funding sources that
contributed to the aMASE study.
Results
By the end of July 2015, recruitment for both clinic and
community surveys had concluded. In total, we recruited 2249
participants from 57 HIV clinics as part of the clinic survey and
we retrieved 1637 complete responses as part of the community
survey. Following data cleaning and analysis, we submitted
initial findings and results for peer review in April 2015.
Discussion
The aMASE study is the first multinational study to specifically
sample migrants from across the globe living in Europe. The
data gathered will provide not only valuable information about
the barriers faced by migrants when trying to access HIV testing,
prevention, treatment, and care, but also data about
postmigration HIV acquisition. A literature review estimated
that postmigration HIV acquisition among migrants from
countries with a generalized epidemic range from 2% in
Switzerland to 62% among migrant black Caribbean men who
have sex with men in Europe [5]. The aMASE study will be the
first to estimate postmigration HIV acquisition among European
migrants living in Europe, as well as those from endemic
regions. These data will provide policy makers and HIV program
managers with a sound evidence base on which to develop HIV
testing and prevention initiatives for these populations.
There were limitations to this study. Clinics from 9 countries
were involved in data collection for the clinic study, and we
recruited participants from 57 clinics. We selected these
countries in part because they have large migrant populations
(including those from Latin America and sub-Saharan Africa);
in 2011, the United Kingdom, Germany, Spain, and Italy were
the destination countries of 60.3% of all immigrants to EU
member states [3]. The selected countries also contain the largest
numbers of nonnationals (not including migrants who acquired
citizenship in their current country of residence) living in the
EU: Germany (7.7 million persons), Spain (5.1 million), Italy
(4.4 million), the United Kingdom (4.9 million), and France
(3.8 million) [3]. In Greece and Belgium, migrants make up a
substantial proportion of the population (7.8% and 11.2%,
respectively). Migrants living in France are a notable omission
from our clinic sample; however, agreements are in place that
will enable us to compare aMASE data with data from similar
studies conducted in France.
Participating clinics were not chosen at random and may not be
representative of clinics throughout their country of location.
Nonetheless, the majority of sites are located in conurbations
with large migrant populations, and the clinic sample is likely
to be broadly representative of migrants accessing health care
within each participating country. Our clinic (and community)
sample is unlikely to be representative of the European migrant
population as a whole in terms of such factors as country of
residence, region of birth, gender, and sexual orientation.
Consequently, a naive analysis of the overall data might
underestimate or overestimate the strength of associations with
our outcomes in the total population, but we believe our strategy
of investigating heterogeneity of associations between countries
and conducting analyses separately within subgroups determined
by these factors, where necessary, will limit the bias in our
findings.
Finally, the long recruitment period for both the clinic and the
community surveys may present a challenge to interpreting the
data. Migrant populations within Europe can fluctuate and
change rapidly. Those recruited at the beginning of the study
may represent a different migration cohort with differing barriers
to accessing care from those recruited toward the end.
The aMASE clinic survey links self-reported data provided by
participants with data from clinical records, which is vital for
the accurate estimation of probable country of HIV acquisition.
Furthermore, the clinical data will also allow us to estimate
factors associated with late diagnosis, recent seroconversion,
and hepatitis coinfection, thereby providing insight into the
barriers and facilitators to earlier testing and access to care for
study populations that have rarely been the sole focus of HIV
research in Europe. The clinic survey will also augment the
evidence base with regard to distal determinants of health such
as poverty and hunger, as well as the sexual health needs of
migrants living with HIV.
The aMASE Study as a whole also provides a useful model for
community participatory methods in research. The community
survey was developed using iterative methods with close
communication between the research team, a panel of
experienced epidemiologists, statisticians, and HIV clinicians,
and an advisory group made up of community activists. Actively
involving the CAG in survey development was time consuming
and presented logistical challenges for the research team (eg,
language barriers, inability to schedule some meetings during
the working day). Those issues notwithstanding, the benefits in
adopting this strategy were clear shortly after the 2014 European
parliamentary elections, in which parties that campaigned on
an anti-immigration platform performed successfully. Without
the endorsement and support of the CAG, a study about the
health of migrants in Europe may have been viewed with
suspicion across the political spectrum. A careful balancing act
between active promotion on migrant-friendly media and
low-level promotion on mainstream media has enabled the CAG
and the research team to promote the study without experiencing
a significant backlash from anti-immigrant organizations.
Community stakeholders will be actively involved in guiding
analysis and disseminating the results of both surveys. A detailed
publication agreement has been drafted that gives
community-based organizations access to community survey
data relevant to their communities. In addition, CAG members
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will assist in creating a policy advocacy information sheet based
on the results of both surveys. This information sheet will
provide community-based organizations with key local and
pan-European health policy advocacy points designed to
improve access to health care for people living with diagnosed
HIV. Involving community stakeholders in this final stage of
the study increases the likelihood that the findings from this
study will be incorporated into policy and practice across
Europe. The results of this study will improve the understanding
of postmigration transmission dynamics and the barriers to
health care for migrants in Europe.
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